NVO240809C123000
- 2.70
- +1.80+200.00%
Novo-Nordisk A/S Newsroom
Novo Nordisk Is Maintained at Outperform by BMO Capital
Novo Nordisk Drops on Q2 Earnings and Sales Miss Despite Raised Outlook
Novo Nordisk Analyst Ratings
Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ
European Equities Traded in the US as American Depositary Receipts Climb Higher in Thursday Trading
Express News | Novo Nordisk Shares Are Trading Higher. The Stock May Be up After Eli Lily Raised Its Guidance, Primarily Driven by the Performance of Mounjaro and Zepbound
Breaking doubts! The 'weight loss miracle drug' continues to be hot, and Eli Lilly and Co's Q2 performance exceeds expectations and guidance is raised again.
$Eli Lilly and Co (LLY.US)$ Eli Lilly announced its Q2 results on Thursday. According to the data, the company's Q2 revenue was $11.3 billion, a year-on-year increase of 36.0%, better than market expectations; EPS was $3.92, also better than market expectations. thanks to the popularity of the popular weight loss drug Zepbound, the company raised its 2024 revenue guidance for the second time this year. Data showed that Zepbound sales in the second quarter were $1.2 billion, exceeding market expectations of $0.819 billion. Eli Lilly currently expects full-year revenue to be between $45.4 billion and $46.6 billion, higher than previous expectations.
Company News for Aug 8, 2024
Trending Stocks Today | Conduit Pharmaceuticals Shoots up 95.45% Pre-Market
Eli Lilly Jumps After Guidance Raise on Weight Loss Momentum
Express News | Novo Nordisk : BMO Cuts Target Price to $160 From $170
European Stocks: Novo Nordisk Lowers Profit Outlook on Subdued Wegovy Sales
As the "tightening storm" hits the consumer sector, how to accurately select stocks in the face of adversity?
After the pandemic, the consumer boom has already dwindled, and investors in large consumer goods companies need to start picking stocks more carefully.
Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk
Top Gap Ups and Downs on Wednesday: NVO, SHOP, ABNB and More
Rebound Day Turned Red and Earnings Helped Declines | Wall Street Today
Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com
Sector Update: Health Care Stocks Fall Late Afternoon
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?